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ABSTRACT
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is initiated by 
steatosis and can progress via fibrosis and cirrhosis to hepatocellular carcinoma (HCC). 
The RNA binding protein HuR controls RNAs at the posttranscriptional level; hepatocyte 
HuR has been implicated in the regulation of diet-induced hepatic steatosis. The present 
study aimed to understand the role of hepatocyte-HuR in NAFLD development and 
progression to fibrosis and HCC.
APPROACH AND RESULTS: Hepatocyte-specific HuR-deficient mice and control HuR-
sufficient mice were fed either a normal diet or a NAFLD-inducing diet. Hepatic lipid 
accumulation, inflammation, fibrosis and HCC development were studied by histology, 
flow cytometry, quantitative PCR and RNA sequencing. The liver lipidome was 
characterized by lipidomics analysis and the HuR-RNA interactions in the liver were 
mapped by RNA immunoprecipitation-sequencing. Hepatocyte-specific HuR-deficient 
mice displayed spontaneous hepatic steatosis and fibrosis predisposition, compared to 
control HuR-sufficient mice. On a NAFLD-inducing diet, hepatocyte-specific HuR-
deficiency resulted in exacerbated inflammation, fibrosis and HCC-like tumor 
development. A multi-omic approach, including lipidomics, transcriptomics and RNA-
immunoprecipitation sequencing revealed that HuR orchestrates a protective network of 
hepatic-metabolic and lipid homeostasis-maintaining pathways. Consistently, HuR-
deficient livers accumulated, already at steady-state, a triglyceride signature resembling 
that of NAFLD livers. Moreover, upregulation of Spp1 and its product osteopontin 
mediated, at least partially, the fibrosis development in hepatocyte-specific HuR 
deficiency on a NAFLD-inducing diet, as shown by experiments utilizing antibody 
blockade of osteopontin.
CONCLUSIONS: HuR is a gatekeeper of liver homeostasis preventing NAFLD-related 
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) affecting up to 30% of the adult population and 
70-80% of obese and diabetic individuals, is associated with dysfunctional hepatic 
metabolism (1, 2). NAFLD ranges from simple intrahepatic fat accumulation (steatosis), 
to non-alcoholic steatohepatitis (NASH), which is characterized by hepatocyte death and 
inflammation and may progress to fibrosis, cirrhosis and hepatocellular carcinoma (HCC) 
(1, 3). Hepatic fibrosis is the main factor determining liver-related mortality in NASH 
patients (4). 
Excessive triglyceride (TAG) accumulation is the initiating process of NAFLD (5). Both, 
plasma non-esterified fatty acids and fatty acids from de novo lipogenesis are utilized for 
TAG synthesis in the liver (5). Liver TAG can be stored as lipid droplets in hepatocytes, 
secreted as very-low-density-lipoprotein particles or hydrolyzed (6). A network of 
enzymes and transcription factors controls hepatic metabolic pathways (2). RNA binding 
proteins (RBP) are integral to the post-transcriptional regulation of gene expression in the 
liver under physiological and pathological conditions (7, 8). However, less is known about 
the cell type-specific function of RBPs in the liver, particularly in hepatocytes. 
The RBP HuR (encoded by Elavl1; embryonic lethal abnormal vision like 1), regulates 
gene expression post-transcriptionally by altering the abundance and use of RNAs that it 
binds to. HuR is present in the nucleus and in the cytoplasm; however, the most 
predominant functions of HuR are associated with its cytoplasmic localization (9, 10). 
Cytoplasmic HuR can promote the stability and translation of mRNAs containing uridine 
or adenine/uridine rich elements in their untranslated termini, although in some cases 
HuR may act in an opposite manner (10, 11). ShRNA-mediated HuR silencing in the liver 
attenuates hepatic stellate cell (HSC) activation and fibrosis development following bile 
duct ligation (12), and HuR is involved in TGF-1-induced HSC activation (13). 
Hepatocyte HuR regulates hepatic steatosis development in response to high fat diet 
feeding (14). However, an in-depth analysis of the role of hepatocyte HuR in regulating 
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We identified HuR here as a master regulator of hepatic homeostasis. Hepatocyte-
specific HuR deletion led to spontaneous steatosis and fibrosis predisposition. Upon 
feeding a NAFLD-inducing diet, hepatocyte-specific HuR-deficient mice developed 
heightened inflammation and fibrosis, which resulted in HCC-like tumor development. 
Mechanistic analysis revealed that HuR regulates a protective hepatic network of 
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METHODS
Mouse experiments
Mice with hepatocyte-specific deletion of HuR (HuRHepKO) in the C57BL/6 background 
were derived by crossing mice with a floxed Elavl1 allele with mice expressing Cre 
recombinase under the control of Albumin promoter (Albumin-Cre). Cre-negative 
littermate mice with Elavl1 floxed alleles (HuRWT) were used as controls. 
HuRWT or HuRHepKO mice were fed a methionine-low, choline-deficient high fat diet (60% 
kcal from fat, 0.1% methionine and choline-deficient diet; 60%-HFD-CD; A06071302, 
Research Diets) for 2 or 6 weeks or a normal diet (ND, 10% kcal fat, normal methionine 
and choline, A08051501, Research Diets) for 6 weeks. Long-term feedings were 
performed with a choline-deficient high fat diet (45% kcal from fat; CD-HFD-45%; 
D05010402, Research Diets) for up to 14 months. 7-10 week old mice of both genders 
were used. Animal experiments were approved by the prefecture of Attica, Greece and 
by the Landesdirektion Sachsen, Germany; animals received humane care according to 
the ‘Guide for the care and use of laboratory animals’. 
Statistical analysis
For analysis, the GraphPad Prism software (GraphPad Inc., La Jolla, CA) was used, 
unless otherwise stated in the Methods. For comparison of two groups, Mann-Whitney U 
test was used. Statistics for tumor incidence was calculated using two-tailed Fisher’s 
exact test. Statistical analysis for lipidomics and RNA sequencing is described in the 
respective sections (in Supplemental Material). Data are expressed as mean±s.e.m. 
Significance was set at P < 0.05.
Detailed methods are in the Supplemental Material.
RESULTS
Hepatocyte-specific HuR deletion in mice promotes hepatic steatosis and fibrosis
To assess the function of HuR in hepatocytes, we generated mice with hepatocyte-
specific HuR deletion (HuRHepKO). Littermate Cre-negative Elavl1 floxed mice (HuRWT) 
were used as controls. Efficient HuR deletion was found in livers of HuRHepKO mice 
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NAFLD-inducing diets. Hepatocyte-specific HuR deficiency resulted in spontaneous 
hepatic steatosis at steady-state (Figure-1A). To clarify if the enhanced steatosis in 
HuRHepKO mice at steady-state was metabolically benign (15) or predisposed to NASH 
and fibrosis, we fed HuRWT and HuRHepKO mice a NAFLD-inducing diet (methionine-low, 
choline-deficient high fat diet, with 60% kcal from fat (60%-HFD-CD)) for 2 or 6 weeks, 
representing early and advanced NAFLD/NASH development, respectively. Both HuRWT 
and HuRHepKO mice on 60%-HFD-CD developed steatosis (Figure-1B). However, 
hepatocyte-specific HuR deficiency exacerbated NAFLD-related fibrosis, as assessed by 
picrosirius red staining of livers upon 2 and 6 weeks of 60%-HFD-CD feeding (Figure-1C-
D). Moreover, hydroxyproline concentration was increased in livers of HuRHepKO mice, 
compared to control mice, upon 6 weeks of 60%-HFD-CD feeding (Figure-1E). We found 
enhanced mRNA expression of fibrosis-related factors, such as genes encoding different 
collagen subtypes as well as Sphk1, Pdgfd, Pdgfb, Pdgfrb, Timp2, Igf1r, Tgfb2 and 
Tgfb1, in HuRHepKO livers compared to HuRWT livers (Figure-1F). 
Analysis of fibrosis development owing to hepatocyte-specific HuR deletion
To provide mechanistic insights for the fibrosis development resulting from hepatocyte 
HuR deletion, we performed RNA sequencing (RNA-seq) of livers from HuRHepKO and 
HuRWT mice at steady-state. Hepatocyte HuR deficiency resulted in downregulation of 
456 genes and upregulation of 593 genes (Figure-2A). Ingenuity Pathway Analysis (IPA) 
revealed that the hepatic fibrosis/HSC activation pathway was the most prominently 
enriched one in the significantly upregulated genes of HuRHepKO livers (Figure-2B). 
Significantly enhanced expression of several genes involved in the hepatic fibrosis/HSC 
activation pathway was found in HuRHepKO livers, compared to HuRWT livers (Figure-2C 
and Figure-S2A). Several pathways related to hepatic fibrosis, such as the PDGF 
signaling pathway, epithelial mesenchymal transition pathway and hepatic fibrosis 
signaling pathway, were enriched in the significantly upregulated genes of HuRHepKO 
livers relative to HuRWT livers (Figure-2B). Gene Set Enrichment Analysis (GSEA) over 
the Molecular Signatures Database displayed a positive correlation between hepatocyte-
specific HuR deficiency and extracellular matrix-associated gene expression and 
epithelial-mesenchymal transition-associated gene expression in the liver (Figure-2D-E 
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and HSCs in vitro. Conditioned medium (CM) derived from HuR-deficient hepatocytes 
promoted the expression of profibrotic genes, such as Acta2, Col1a1, Col3a1, Col6a3 
and Timp2, in wildtype HSCs, compared to treatment with CM from HuRWT hepatocytes 
(Figure-S2B). Together, hepatocyte-specific HuR deficiency promotes HSC activation, 
thereby contributing to fibrosis predisposition of HuRHepKO livers. 
IPA revealed overrepresentation of several pathways in the significantly downregulated 
genes of HuRHepKO livers, including cholesterol biosynthesis pathways (Figure-2F). The 
protective bile acid (BA)-activated FXR/RXR pathway was also enriched in the 
significantly downregulated genes of HuR-deficient livers (Figure-2F-G). The FXR 
(farnesoid X-activated) receptor pathway regulates lipid homeostasis and protects 
against liver fibrosis (1, 16-19). FXR activation in hepatocytes increases triglyceride 
clearance and blocks SREBP1-mediated lipogenesis, whereas FXR signaling in HSCs 
inhibits their activation and protects against fibrogenesis (1, 17, 20). IPA also revealed 
enrichment of the retinol biosynthesis pathway in the significantly downregulated genes 
of HuR-deficient livers (not shown); hence potentially decreased retinoic acid levels may 
further contribute to reduced FXR/RXR activation in HuR-deficient hepatocytes (21).
Analysis by qRT-PCR for selected genes, identified as differentially expressed due to 
hepatocyte-specific HuR deficiency by RNA-seq, confirmed upregulation of expression of 
genes involved in the hepatic fibrosis/hepatic stellate cell activation pathway and 
downregulation of expression of genes involved in the FXR/RXR activation pathway 
(Figure-2H). 
Collectively, hepatocyte HuR deficiency promotes transcriptomic alterations culminating 
to HSC activation and fibrosis (Figure-2C-E), thereby underlying the fibrosis 
predisposition of HuRHepKO mice at steady-state and leading to exacerbated fibrosis upon 
feeding a NAFLD-inducing diet.
Hepatocyte-specific HuR deletion promotes HCC-like tumor development
NAFLD-related fibrosis predisposes to HCC (3). We found that the tumor 
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HuRHepKO livers compared to HuRWT livers at steady-state (Figure-2B). Furthermore, the 
RNA-seq data obtained from HuRWT and HuRHepKO livers of steady-state mice were 
subjected to upstream regulator analysis using the IPA software (Supplemental table-2 
and Figure-S3). The -catenin (CTNNB1) pathway, involved in HCC pathogenesis (22), 
was predicted to be activated in HuRHepKO livers, compared to HuRWT livers 
(Supplemental table-2 and Figure-S3). Although HuR expression is increased in HCC 
and various other cancers and correlates with parameters of tumor progression (23), our 
data show that at steady-state and in NAFLD, HuR contributes to maintenance of 
hepatocyte homeostasis. 
To study whether the predisposition towards hepatic steatosis and fibrosis due to 
hepatocyte-specific HuR-deficiency may promote NASH-related cancer development, we 
fed HuRHepKO and HuRWT mice with another NAFLD-inducing choline-deficient, high fat 
diet (with 45% kcal from fat, designated CD-HFD-45% hereafter) for up to 14 months. We 
chose the milder CD-HFD-45% model (24), as it displays a slower progression of liver 
disease pathogenesis, resembling the chronicity that governs the development of 
sequelae of human NAFLD, such as HCC. Plasma levels of aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) were elevated in HuRHepKO mice compared to 
HuRWT mice, following the CD-HFD-45% feeding (Figure-3A-B), indicating enhanced liver 
injury. HuRHepKO livers showed an increased NASH activity score and exacerbated 
fibrosis, compared to HuRWT livers (Figure-3C-D). Strikingly, a portion of HuRHepKO (9/54) 
but no HuRWT (0/27) mice developed HCC-like tumors, as assessed histo-pathologically 
(Figure-3E-F). The positive AFP (alpha-fetoprotein) staining (Figure-3G), together with 
the characteristic absence of reticulin staining (Figure-3H) in the tumor tissues of 
HuRHepKO mice further underlined the resemblance to HCC (25, 26). Hepatic inflammation 
was increased in HuR-deficient mice compared to control mice, as assessed 
histologically (Figure-4A). Flow cytometry analysis for immune cell populations in the liver 
revealed significant increases in the numbers of CD8+ T cells (CD8+CD4- cells), NK1.1+ 
NKT cells (CD4-CD8-NK1.1+) and infiltrating macrophages (Gr1-CD11b+CD11c-
MHCII+Ly6c+) (Figure-4B-G and Figure-S4). Together, HuRHepKO mice on long-term 
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to HCC-like tumor development, hence recapitulating the complete sequence of NAFLD-
related pathogenesis and sequelae.
A NAFLD-like hepatic lipid signature owing to hepatocyte HuR deficiency
To further discern the spontaneous steatosis predisposing to fibrosis due to hepatocyte-
specific HuR deficiency, we performed shotgun lipidomic analysis of livers obtained from 
HuRHepKO and HuRWT mice fed a ND or a 60%-HFD-CD. Shotgun lipidomics allow for 
detailed analysis of storage (triacylglycerides, TAG; cholesterol ester, CE) and non-
storage lipids (all lipid classes other than TAG and CE). Consistent with the histological 
analysis (Figure-1A), the percentage of storage lipids was higher in HuRHepKO livers 
compared to HuRWT livers fed a ND (Figure-5A). Analysis of the lipid classes 
demonstrated that CEs and TAGs were enhanced in HuRHepKO livers compared to HuRWT 
livers (Figure-5B). Both, non-storage lipids and storage lipids of the two groups on ND 
separated from each other in the principal component analysis (Figure-5C-D). Since the 
storage lipids were enhanced in the absence of hepatocyte HuR, we further studied 
alterations in storage lipids species. The abundance of several TAG and CE species was 
upregulated in the absence of HuR (Figure-5E). When comparing the lipidome of livers of 
HuRWT mice, which were fed either a 60%-HFD-CD or a ND, we found that 60%-HFD-CD 
feeding also led to increased TAG and CE levels (Figure-S5A-C). Furthermore, several 
TAG and CE species were enriched in NAFLD livers, compared to healthy livers of 
HuRWT mice (Figure-5F). 
All TAG species and some CE species, which were significantly increased at steady-state 
in HuRHepKO livers (Figure-5E, bars outlined in red) were also upregulated in HuRWT livers 
upon 60%-HFD-CD feeding (Figure-5F, bars outlined in red). Specifically, TAG_48:0, 
TAG_50:1, TAG_51:3, TAG_53:3, TAG_53:2, TAG_50:4, TAG_53:4, TAG_52:3, 
TAG_56:6, TAG_54:4, TAG_58:3, TAG_52:4, TAG_54:5, TAG_52:5, TAG_54:7, 
TAG_54:6, TAG_50:5, TAG_52:6, TAG_55:4, TAG_54:2, TAG_58:9, CE_18:2, CE_18:1, 
CE_16:0 and CE_22:6, which were increased due to hepatocyte-specific HuR deletion at 
steady-state, were also altered in the same manner in livers of HuRWT mice upon feeding 
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phenotype of HuR-deficient livers at steady-state (genotype-driven change) is very similar 
to that of HuRWT livers with NAFLD (diet-driven change, Figure-5G). In addition to 
phenocopying the TAG microenvironment of WT NAFLD livers (Figure-5G), the HuR-
deficient livers at steady-state displayed a TAG signature similar to human NAFLD livers 
(27, 28). During human NAFLD, TAG_50:1 is enriched (28-31); similarly we found that 
this TAG was increased in HuR-deficient livers at steady-state (Figure-5E). Furthermore, 
TAG_48:0, TAG_52:3, TAG_54:4, TAG_52:4, TAG_54:5, TAG_56:6, TAG_52:5, 
TAG_54:7, TAG_54:2, CE_22:6 and CE_18:2, which were enhanced in HuR-deficient 
livers at steady-state (Figure-5E), are upregulated either in the liver or in circulation in 
human NAFLD (27, 28, 30, 31). Therefore, hepatocyte-specific HuR deficiency leads to a 
spontaneous phenotype that phenocopies the TAG signature within the hepatic 
microenvironment characteristic of human NAFLD. Lipidomic analysis of NAFLD livers 
(60%-HFD-CD feeding) revealed no differences in storage lipids between the two 
genotypes (Figure-5H-I). Together, hepatocyte HuR deficiency promotes the 
accumulation of storage lipids in the liver under steady-state conditions resulting in a 
lipidomic signature similar to that of wild-type livers with NAFLD as well as of human 
NAFLD livers.    
The HuR-dependent hepato-protective network
Our phenotypic and multi-omic analysis demonstrated that hepatocyte-specific HuR 
deficiency promotes liver steatosis associated with a pro-fibrotic predisposition at steady-
state, thereby leading to exacerbated fibrosis and HCC-like tumor development upon 
feeding a NAFLD-inducing diet. To mechanistically connect HuR functions as an RBP to 
RNA changes incurred by its deficiency in the liver, we next mapped the RNA interactors 
of HuR ribonucleoprotein (RNP) complexes in mouse livers by RNP-immunoprecipitation 
and RNA sequencing (RIP-seq). RIP was performed in cytoplasm-enriched extracts from 
healthy livers of wildtype mice using an anti-HuR antibody or an isotype matched IgG as 
control (Figure-S6A). Sequencing analysis of immunoprecipitated RNAs normalized to 
their expression values revealed 1380 mRNAs as enriched in HuR-RNPs with a fold 
change >1.5 and a p<0.05 over the IgG controls (Supplemental table-3). The quality of 
the RIP-seq was evaluated via the successful validation of 7 out of 8 mRNAs tested as 
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samples (Figure-S6B). Putative HuR targets were used to create functional pathway 
networks (Figure-6 and Supplemental tables-4-6). 
Cytoplasmic HuR binds to its target mRNAs and promotes their use by augmenting 
mRNA stability or translation although in some cases it may act in a negative fashion (11, 
32). Several target mRNAs from the RIP-seq were associated with hepatic metabolism, 
including glycerolipid, cholesterol, long chain fatty acid, monocarboxylic acid and 
carbohydrate metabolism (Figure-6 and Supplemental tables-4-6). The top most 
significant “Biological Process” identified via Gene Ontology analysis of the RIP-seq data 
was the monocarboxylic acid metabolic process, which contained 102 targets (Figure-6 
and Supplemental table-5). In Gene Ontology, monocarboxylic acid metabolic process is 
a parent term for the bile acid metabolic process, among others. Thus, the RIP-seq 
findings are in agreement with the RNA-seq data, which showed that expression of genes 
involved in cholesterol biosynthesis and in the BA-activated FXR/RXR pathway were 
diminished due to hepatocyte HuR deficiency (Figure-2F-G). 
The hepatic targets of HuR identified here are involved in various facets of BA 
metabolism and recycling. Besides mRNAs of genes mediating BA synthesis, such as 
Cyp7a1 and Cyp7b1, HuR binds to mRNAs of transmembrane transporters of BA, such 
as Abcc2, Slco1b2, Abcb11 and Slco1a4, and of BA conjugating enzymes, such as 
Slc27a2 (Supplemental table-3). We therefore measured BA levels in livers of HuRHepKO 
and HuRWT mice at steady-state. From the BAs that could be detected, 
taurochenodeoxycholic acid (TCDCA) and tauroursodeoxycholic acid (TUDCA) were 
downregulated in HuR-deficient livers compared to HuR sufficient livers (Figure-S7A-B). 
Noteworthy, both TUDCA and TCDCA have been shown to activate FXR (33, 34). 
Contrastingly, other BAs, such as tauromuricholic acid (alpha+beta) (TMCA +) or 
taurocholic acid (TCA) were not altered due to HuR deficiency (Figure-S7C-D). 
Additionally, mRNAs regulating the function of the endoplasmic reticulum (ER), protein 
processing in the ER and ER stress response pathway were HuR targets (Figure-6 and 
Supplemental tables-3-6). IRE1 (encoded by Ern1), which is one of the arms of the 
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operative in the UPR, were HuR targets (Supplemental tables-3-6). Moreover, Herpud1, 
Serp1, Amfr, Bfar, Herpud2, Atf4, Stub1, Vapb, Eif2ak2, Ep300 and Hspa13, which are 
genes that function in the ER’s UPR are HuR targets (Supplemental tables-3-6). Hence, 
several of the factors and pathways identified here to be regulated by HuR in the liver, 
including the ER stress response, BA metabolism and FXR pathways, have been 
implicated in hepatic homeostatic metabolism and function, thereby portraying a central 
role of HuR in liver homeostasis (16-18, 35). 
Continuing our search for protective pathways, which could fail in the absence of HuR, 
we sought to identify mRNAs that were bound to and regulated by HuR. Therefore, we 
compared the RNA-seq (Figure-2) with the RIP-seq data (Figure-6). Out of the 1049 
genes that were significantly deregulated in HuR deficiency (Figure-2A), mRNAs of 110 
genes were identified as HuR targets by RIP-seq (Figure-S8A), suggesting that HuR may 
bind to and regulate their use. Analysis of these 110 targets using the online automated 
meta-analysis tool, Metascape, revealed that the steroid biosynthetic process, cofactor 
metabolic process, biological oxidations, lipid homeostasis and protein folding were the 
top five enriched pathways (Figure S8B). The steroid biosynthetic process, which was the 
top significant pathway, further consisted of cholesterol metabolic process, sterol 
metabolic process, lipid biosynthetic process, metabolism of lipids, fatty acid metabolic 
process and monocarboxylic acid metabolic process as sub-categories, among others. 
The lipid homeostasis pathway consisted of plasma lipoprotein remodeling, lipid storage, 
lipid localization, cholesterol homeostasis, cholesterol efflux, triglyceride metabolic 
process, lipid transport and regulation of lipid localization as sub-categories, among 
others. However, pathways that are known to directly contribute to hepatic-fibrosis 
development were not enriched (Figure-S8B), thereby suggesting that the 
overrepresented hepatic fibrosis/HSC activation pathway due to hepatocyte-specific HuR 
deficiency (Figure-2B-C) is likely secondary to other alterations (e.g. in lipid metabolism) 
in hepatocytes. Hence, HuR regulates a hepato-protective lipid metabolic network in the 
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Osteopontin partially mediates fibrosis development in hepatocyte-specific HuR 
deficiency
Our data so far suggest that alterations in HuR-deficient hepatocytes may trigger HSC 
activation and fibrosis, possibly in a paracrine fashion. We therefore examined the RNA-
seq data of HuRWT and HuRHepKO livers (Figure-2), in order to identify upregulation in 
HuR-deficient hepatocytes of mRNA of secreted factors that could contribute to HSC 
activation and fibrosis. Amongst other genes implicated in fibrosis development that were 
upregulated by hepatocyte-specific HuR deficiency, we chose to analyze the potential 
role of Spp1 and its product osteopontin (OPN), as Spp1 was within the top five 
significantly upregulated genes (ranked based on the adjusted p value) in HuRHepKO 
livers, compared to HuRWT livers (not shown), and as OPN is known to promote HSC 
activation and fibrogenesis (36, 37). Consistent with the RNA-seq data, qRT-PCR 
analysis verified that Spp1 mRNA was increased in HuRHepKO as compared to HuRWT 
livers, both at steady state and upon 60%-HFD-CD diet feeding (Figure-7A-B). 
Additionally, primary hepatocytes from HuRHepKO mice displayed higher OPN protein 
secretion than cells from HuRWT mice (Figure-7C). 
Previously, hepatocyte Notch activation was shown to induce fibrosis by increasing Sox9-
dependent hepatocyte expression of OPN, which promotes HSC activation (36). 
Consistent with this study, Hes1 and Sox9, which are downstream targets of the Notch 
pathway, and Jag1, which encodes the Notch ligand jagged-1, were significantly 
upregulated in HuRHepKO livers compared to HuRWT livers, based on the RNA-seq (not 
shown). The upregulation of Hes1, Sox9 and Jag1 expression in HuRHepKO livers was 
confirmed by qRT-PCR (Figure-S9A-C). According to the RIP-seq analysis, Jag1 is a 
direct target of HuR in the liver (Supplemental Table-3), suggesting that HuR may 
negatively regulate Jag1 expression. Contrastingly, expression of other Notch pathway 
components, such as the Notch receptors 1-4, was unchanged in HuR-deficient livers 
(Figure-S9D-G). These findings indicate that due to the potential direct regulation of Jag1 
expression by HuR, hepatocyte-specific HuR deficiency results in upregulation of Jag1 











This article is protected by copyright. All rights reserved
Therefore, we next addressed whether the increase in OPN may promote HSC activation 
and fibrosis owing to HuR deficiency. To this end, HuRHepKO mice were treated with an 
OPN-neutralizing antibody, or control antibody, while being fed with 60%-HFD-CD diet. 
OPN blockade resulted in a tendency towards reduced fibrosis in HuRHepKO mice, 
compared to control antibody treatment, as shown by picrosirius staining (Figure-7D-E). 
Additionally, qRT-PCR analysis for expression of fibrosis-related genes (Figure-S10) 
supported the partial reduction in fibrosis in HuRHepKO mice by treatment with the OPN 
antibody. Together, increased OPN may, at least partially, mediate fibrosis development 
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DISCUSSION
We identified here hepatocyte HuR as an integral factor to the maintenance of liver 
metabolic homeostasis. We show that HuR regulates a network of homeostatic hepatic 
processes, including lipid and BA metabolism, thereby protecting against hepatic 
steatosis, fibrosis and HCC development. Strikingly, hepatocyte-specific HuR deficiency 
resulted in spontaneous hepatic steatosis, accumulation of a TAG signature resembling 
that of human NAFLD livers, HSC activation and predisposition to fibrosis. Hepatocyte-
specific HuR-deficient mice on NAFLD-inducing diets displayed aggravated hepatic 
fibrosis and HCC-like tumor development. Hence, hepatocyte-specific HuR deficiency 
recapitulates the whole sequence of NAFLD pathology upto HCC development. Our 
findings unequivocally position HuR as a central player of hepatic homeostasis.
Cytoplasmic HuR interacts with its target mRNAs and either promotes mRNA stability, 
upregulates mRNA translation or can suppress either of those functions in specific 
tissues (10, 11, 32, 38). Here, we show that in cytoplasm-enriched liver fractions, HuR 
interacts with mRNAs of genes involved, amongst others, in lipid transport/metabolism, 
BA transport/metabolism, cholesterol metabolism, or the ER stress response pathway, 
hence, potentially regulating several homeostatic hepatic pathways. A comprehensive 
analysis involving transcriptomics, lipidomics and mass spectrometric BA measurement 
verified that HuR is a regulator of aforementioned metabolic pathways. 
Lipidomic analysis revealed that the TAG species that were significantly increased at 
steady-state due to hepatocyte HuR deficiency were also increased in livers of WT mice 
upon feeding a NAFLD-inducing diet. Importantly, substantial similarities were observed 
between the storage lipid signature of HuR-deficient livers at steady-state and the 
lipidomic alterations in human NAFLD (27-31). TAG_48:0, TAG_50:1, TAG_52:3, 
TAG_54:4, TAG_52:4, TAG_54:5, TAG_56:6, TAG_52:5, TAG_54:7, TAG_54:2, 
CE_22:6 and CE_18:2, which were upregulated in HuR-deficient livers at steady-state, 
are upregulated in human NAFLD as well (27-31). Together, our findings demonstrate 
that the lipidomic signature of mouse NAFLD induced by the 60%-HFD-CD has 
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deletion of a single RBP at steady-state. This finding suggests that HuRHepKO mice may 
represent an appropriate model for studying NAFLD in the future.
The RIP-seq analysis showed that mRNAs of genes involved in BA synthesis, 
conjugation and transport are targets of HuR-RNPs. Specifically, the rate-limiting enzyme 
in BA synthesis Cyp7a1, the enzyme responsible for BA conjugation Slc27a2, and BA 
transporters Abcb11, Slco1a4 and Slco1b2, among others, were HuR targets. We 
corroborated the RIP-seq data by measuring hepatic BA levels. The BA TCDCA and 
TUDCA were diminished in HuR-deficient livers at steady-state compared to HuRWT 
livers. Previous studies have described the hepato-protective role of TUDCA in the 
context of NAFLD by inhibiting ER stress (39, 40), and treatment of genetically obese 
mice with TUDCA reduced hepatic steatosis by regulating genes involved in de novo 
lipogenesis (41). Both TUDCA and TCDCA are activators of FXR (33, 34); consistently, 
the BA-activated FXR/RXR pathway was overrepresented in the significantly 
downregulated genes in HuR-deficient livers, as assessed by RNA-seq. Hepatic FXR is a 
master regulator of lipid homeostasis and protects against NASH and its expression is 
inversely correlated to NASH severity (1). Together with previous findings that activation 
of FXR in hepatocytes leads to HuR upregulation (42), our present data may point to a 
possible feed-forward hepato-protective loop involving the FXR pathway and HuR. 
Genes involved in the hepatic fibrosis/HSC activation pathway were upregulated in HuR-
deficient livers at steady-state, reflecting the fibrosis predisposition due to HuR 
deficiency. However, mRNAs contributing to the hepatic fibrosis/HSC activation pathway 
that were upregulated in HuR-deficient livers were not cytoplasmic-targets of HuR in the 
liver. This suggests that the upregulated hepatic fibrosis/HSC activation pathway due to 
hepatocyte-specific HuR deficiency is likely secondary to the metabolic alterations in 
hepatocytes, as lipid accumulation in hepatocytes can promote HSC activation in a 
paracrine manner (4, 43-45). In support of the hypothesis that hepatocyte HuR regulates 
HSC activation and fibrosis in a paracrine fashion were our findings that HuR-deficient 
hepatocytes displayed higher Spp1 expression and increased secretion of OPN, which 
promotes HSC activation and fibrosis (36) and that pharmacological OPN blockade in 
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recent study demonstrated that pro-fibrotic OPN expression by hepatocytes is enhanced 
by hepatocyte Notch activation in a Sox9-dependent manner (36). Consistently, we found 
that the expression of the downstream targets of the Notch pathway, Hes1 and Sox9 
were upregulated in HuR-deficient livers. Furthermore, expression of Jag1, encoding 
jagged-1, was elevated in HuR-deficient livers. Interestingly, we identified Jag1 as a 
direct target of HuR in the liver by RIP-seq, suggesting that HuR may negatively regulate 
Jag1 expression. Therefore, we conclude that activation of the Jag1/Notch-signaling 
pathway resulting in increased Spp1 expression and OPN secretion due to hepatocyte 
HuR deficiency may, at least partially, mediate the increased HSC activation and fibrosis 
of HuRHepKO mice compared to their HuR-sufficient littermates, although the contribution 
of further pro-fibrotic pathways cannot be excluded and merits further investigation. 
Furthermore, whether the disrupted lipid metabolism and/or the reduced FXR/RXR 
activation in HuR-deficient hepatocytes are functionally linked to the increased pro-fibrotic 
Jag1/Notch/OPN pathway requires future investigation.
Interestingly, long-term feeding with a NAFLD-inducing diet not only aggravated 
inflammation and fibrosis in HuRHepKO mice, but, importantly, led to NASH-related HCC 
development in a portion of HuRHepKO mice. Previous studies have shown that HuR was 
upregulated in livers from cirrhotic patients with HCC and that HuR inhibits apoptosis, 
promotes cell proliferation, cell cycle progression and hypoxia-induced glycolytic switch in 
HCC cells (23, 46-48). However, those studies have only investigated the function of HuR 
in HCC cells or in the context of established HCC. Our data show that hepatocyte-
specific HuR deletion results in predisposition to NAFLD-related HCC. Hence, at steady-
state, HuR exerts a protective function, supporting hepatocyte homeostasis. 
The two NAFLD-inducing diets used in the present study (60%-HFD-CD and CD-HFD-
45%) are based on choline deficiency and have therefore some limitations with regards to 
recapitulating human NAFLD pathology. It would be worth investigating the role of 
hepatocyte-specific HuR deficiency in the context of NAFLD development and 
progression by using alternative NAFLD/NASH-inducing diets, such as a high cholesterol 
diet complemented with fructose-containing drinking water (36, 44) in future studies. 
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liver homeostasis, contributing to deceleration of diet-induced NASH and HCC 
development by regulating a hepato-protective metabolic network. Therefore, appropriate 
modulation of HuR actions could be harnessed therapeutically in the context of 
prevention of NAFLD-related sequelae.
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FIGURE LEGENDS
Figure 1. Hepatocyte-specific HuR deletion promotes hepatic steatosis and fibrosis 
development
(A) H&E staining of livers from HuRWT and HuRHepKO mice at steady-state (fed a normal 
diet (ND) for 6 weeks). Scale bars, 100 µm.
(B) Representative images of H&E stained livers of HuRWT and HuRHepKO mice, which 
were fed a 60%-HFD-CD for 2 weeks. Scale bars, 100 µm. 
(C) Representative images and (D) quantification of picrosirius red staining in livers of 
HuRWT and HuRHepKO mice, which were fed a 60%-HFD-CD for 2 weeks (2 w) or 6 weeks 
(6 w). Scale bars in C, 100 µm. HuRWT mice fed a 60%-HFD-CD for 2 weeks, n = 7 mice; 
HuRHepKO mice fed 60%-HFD-CD for 2 weeks, n = 10 mice; HuRWT mice fed 60%-HFD-
CD for 6 weeks, n = 11 mice; HuRHepKO mice fed 60%-HFD-CD for 6 weeks, n = 12 mice. 
*P < 0.05, ***P < 0.001. Data are presented as mean ± s.e.m. Mann-Whitney U test. 
(E) Quantification of hepatic hydroxyproline levels in HuRWT and HuRHepKO mice, which 
were fed a 60%-HFD-CD for 6 weeks. The data are presented as µg / mg of liver. HuRWT 
mice, n = 11 mice; HuRHepKO mice, n = 12 mice. **P < 0.01.  Data are presented as mean 
± s.e.m. Mann-Whitney U test.
(F left and F right) Genes encoding fibrosis-related molecules were analyzed by qRT-
PCR in livers of HuRWT and HuRHepKO mice, which were fed a 60%-HFD-CD for 6 weeks. 
Gene expression was normalized to B2m (beta-2 microglobulin; F left) or 18S (F right). 
Data are presented relative to the respective HuRWT mice, set as 1. HuRWT mice, n = 8 
mice; HuRHepKO mice, n = 5 mice. Col1a1, collagen type 1 alpha 1; Sphk1, sphingosine 
kinase 1; Tgfb1, transforming growth factor beta1; Col3a1, collagen, type III, alpha 1; 
Col1a2, collagen, type I, alpha 2; Col4a5, collagen, type IV, alpha 5; Col4a2, collagen, 
type IV, alpha 2; Col4a1, collagen, type IV, alpha 1; Col6a3, collagen, type VI, alpha 3; 
Col4a4, collagen, type IV, alpha 4; Col27a1, collagen, type XXVII, alpha 1; Col6a1, 
collagen, type VI, alpha 1; Col5a2, collagen, type V, alpha 2; Pdgfd, platelet-derived 
growth factor, D polypeptide; Pdgfb, platelet derived growth factor, B polypeptide; Pdgfrb, 
platelet derived growth factor receptor, beta polypeptide; Timp2, tissue inhibitor of 
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factor I receptor. *P < 0.05, **P < 0.01. Data are presented as mean ± s.e.m. Mann-
Whitney U test.
Figure 2. Fibrosis predisposition due to hepatocyte-specific HuR deletion 
(A-G) RNA sequencing of livers from HuRWT and HuRHepKO mice at steady-state (fed a 
ND for 6 weeks) (n = 4 mice / group). 
(A) Volcano plot shows the distribution of the adjusted P values (-Log10 (adjusted P 
value)) and the fold change (Log2 FC). Significantly upregulated genes are in red and 
downregulated genes are in blue, in total 593 genes were upregulated and 456 genes 
were downregulated in HuRHepKO livers as compared to HuRWT livers (adjusted P value < 
0.05, Benjamini-Hochberg correction). 
(B) Ingenuity pathway analysis (IPA) was performed using the significantly upregulated 
genes in the HuRHepKO livers, as compared to HuRWT livers (adjusted P value < 0.05, 
Benjamini-Hochberg correction). The top 25 enriched pathways are shown.
(C) Significantly upregulated genes in HuRHepKO livers as compared to HuRWT livers that 
belong to the hepatic fibrosis and hepatic stellate cell activation pathway were plotted in a 
heat map, using the online tool Morpheus. The colour scale represents the Z score.
(D) Gene set enrichment analysis (GSEA) shows a positive correlation between 
hepatocyte-specific HuR deficiency and extracellular matrix related genes. NES, 
normalized enrichment score.
(E) GSEA shows a positive correlation between hepatocyte-specific HuR deficiency and 
epithelial-mesenchymal transition related genes. 
(F) IPA was performed using the significantly downregulated genes in the HuRHepKO 
livers, as compared to HuRWT livers (adjusted P value < 0.05, Benjamini-Hochberg 
correction). The top 25 overrepresented pathways in the significantly downregulated 
genes in the HuRHepKO livers are shown.
(G) Significantly downregulated genes in HuRHepKO livers as compared to the HuRWT 
livers that belong to the FXR/RXR pathway were plotted in a heat map, using the online 
tool Morpheus. The colour scale represents the Z score.
(H) Confirmation qRT-PCR was performed with selected genes that were significantly 
upregulated or downregulated in the RNA sequencing (Panels A-G). Gene expression 
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HuRWT mice, set as 1. Pdgfb, platelet derived growth factor B polypeptide; Pdgfrb, 
platelet derived growth factor receptor beta polypeptide; Timp2, tissue inhibitor of 
metalloproteinase 2; Col1a1, collagen type I alpha 1; Col3a1, collagen type III alpha 1; 
Slc10a2, solute carrier family 10 member 2; Hpx, hemopexin. n = 4 mice / group. *P < 
0.05. Data are presented as mean ± s.e.m. Mann-Whitney U test.
Figure 3. Hepatocyte-specific HuR deletion promotes HCC-like tumor development 
in mice following long term CD-HFD-45% feeding
(A) Plasma AST and (B) ALT levels in HuRWT and HuRHepKO mice that were fed a CD-
HFD-45% for 14 months. (C) Higher NASH activity score was calculated in HuRHepKO 
livers as compared to HuRWT livers after CD-HFD-45% feeding for 14 months. (D) 
Representative images of Masson Trichrome staining (MAS) performed in livers of 
HuRWT and HuRHepKO mice that were fed a CD-HFD-45% for 14 months. Scale bars, 100 
µm. (E) Graph shows the presence (1) or absence (0) of tumors in livers of HuRWT and 
HuRHepKO mice that were fed a CD-HFD-45% for 14 months. In the HuRWT group 0 / 27 
mice developed tumors and in the HuRHepKO group 9 / 54 mice developed tumors. (F) 
Representative histology image of a HCC-like tumor in a HuRHepKO liver stained with 
H&E. Scale bar, 100 μm. (G) Representative image of a HCC-like tumor in a HuRHepKO 
liver stained for AFP (alpha-fetoprotein). Scale bar, 100 μm. (H) Representative images 
of a HCC-like tumor in a HuRHepKO liver stained for reticulin; the reticulin framework is 
typically reduced or incomplete in HCC. Different magnifications of the same tissue 
section are shown. Scale bars, 100 µm. 
Data are presented as mean ± s.e.m. n = 27 mice in HuRWT group and n = 54 mice in 
HuRHepKO group. Mann-Whitney U test (A-C) or two-tailed Fisher’s exact test (E). ****P < 
0.0001,*P < 0.05.
Figure 4. Enhanced accumulation of immune cells in livers of HuRHepKO mice 
following long term CD-HFD-45% feeding
(A) Inflammation score based on Batts-Ludwig system was performed in livers of HuRWT 
and HuRHepKO mice following CD-HFD-45% feeding for 14 months. N = 27 mice in HuRWT 
group and n = 54 mice in HuRHepKO group. (B-G) Flow cytometry analysis of CD4+ T cells 
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(Gr1+CD11b+), monocytes (Gr1-CD11b+CD11c-MHCII-Ly6c+) and infiltrating 
macrophages (Gr1-CD11b+CD11c-MHCII+Ly6c+) was performed in livers of HuRWT and 
HuRHepKO mice following CD-HFD-45% feeding for 14 months. n = 6 mice in HuRWT group 
and n = 6 mice in HuRHepKO group. ****P < 0.0001,*P < 0.05. Data are presented as mean 
± s.e.m. Mann-Whitney U test.
Figure 5. A NAFLD-like hepatic lipid signature owing to hepatocyte HuR deficiency
(A-I) Lipidomic analysis of livers from HuRWT and HuRHepKO mice at steady-state (fed a 
ND for 6 weeks; n = 5 mice / group) and of livers from HuRWT and HuRHepKO mice with 
NAFLD (fed a 60%-HFD-CD for 2 weeks; n = 6 mice / group). 
(A-E) Comparison of HuRWT and HuRHepKO mice at steady-state.
(A) Percentages of hepatic-storage lipids (TAG and CE) and non-storage lipids (all other 
lipid classes present in panel B except for TAG and CE) in HuRWT and HuRHepKO mice at 
steady-state, depicted as pie charts.
(B) Alterations in hepatic-lipid classes in HuRWT and HuRHepKO mice at steady-state, 
presented as mean pmol / µg of total protein. CE, cholesterol ester; Cer, ceramide; Chol, 
cholesterol; CL, cardiolipin; DAG, diacylglycerol; HexCer, hexosylceramide; LPA, lyso-
phosphatidate; LPC, lyso-phosphatidylcholine; LPE, lyso-phosphatidylethanolamine; LPE 
O-, lyso-phosphatidylethanolamine-ether; LPI, lyso-phosphatidylinositol; LPS, lyso-
phosphatidylserine; PA, phosphatidate; PC, phosphatidylcholine; PC O-, 
phosphatidylcholine-ether; PE, phosphatidylethanolamine; PE O-, 
phosphatidylethanolamine-ether; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, 
phosphatidylserine; SM, sphingomyelin; TAG, triacylglycerol. *P < 0.05. Data are 
presented as mean ± s.e.m.   
(C) Principal component analysis (PCA) of hepatic-non-storage lipids (all other lipid 
classes present in panel B except for TAG and CE) from HuRWT and HuRHepKO mice at 
steady-state shows that the two conditions segregate along dimension 2, PC2. ***P < 
0.001. 
(D) PCA of hepatic-storage lipids (TAG and CE) from HuRWT and HuRHepKO mice at 
steady-state shows that the two conditions segregate along the first dimension, PC1. **P 
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(E) Alterations in storage lipid species (TAG and CE species) in the livers of HuRHepKO 
mice at steady-state as compared to HuRWT mice at steady-state. Y axis depicts the Log2 
fold change of the lipids (HuRHepKO / HuRWT; Log2 FC was calculated using the pmol / µg 
values) and the X axis depicts the lipid species. Only the significantly (P < 0.05) altered 
storage lipid species are shown. The red color (in the font and in the outline of the bars) 
indicates the TAG and CE species that were also significantly altered in HuRWT mice 
when fed a 60%-HFD-CD diet as compared to ND (data shown in panel F). 
(F) Comparison of livers from HuRWT mice with NAFLD (fed a 60%-HFD-CD) with HuRWT 
mice at steady-state (fed a ND). The significantly (P < 0.05) altered storage lipid species 
(TAG and CE species) in the liver are shown. Y axis depicts the Log2 fold change of the 
lipids (60%-HFD-CD / ND; Log2 FC was calculated using the pmol / µg values) and the X 
axis depicts the lipid species. The red color (in the font and in the outline of the bars) 
indicates the TAG and CE species that were also significantly altered in the HuR-deficient 
livers as compared to HuR sufficient livers at steady-state (data shown in panel E). 
(G) Storage lipid species, which were significantly upregulated in both comparisons (i) 
HuRWT mice with NAFLD (fed a 60%-HFD-CD) as compared to HuRWT mice at steady-
state (fed a ND), hence, depicting 60%-HFD-CD-driven changes (as shown in panel F) 
and (ii) HuRHepKO mice compared to HuRWT mice at steady-state, hence, depicting 
genotype-driven changes (as shown in panel E), were plotted against each other using 
the Log2 fold change. 
(H-I) Comparison of HuRWT and HuRHepKO mice with NAFLD (fed a 60%-HFD-CD).
(H) Hepatic-lipid classes in HuRWT and HuRHepKO mice with NAFLD (fed a 60%-HFD-CD), 
presented as mean pmol / µg of total protein. Abbreviations for the lipid classes are the 
same as in panel B. Data are presented as mean ± s.e.m. 
(I) Percentages of hepatic-storage lipids (TAG and CE) and non-storage lipids (all lipid 
classes present in panel H except TAG and CE) in HuRWT and HuRHepKO mice with 
NAFLD (fed a 60%-HFD-CD).
Figure 6. Mapping the RNA interactors of HuR ribonucleoprotein complexes in the 
liver
RIP-seq was performed in healthy livers of WT C57BL/6 mice using a HuR antibody or an 
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HuR and these HuR targets were used to create functional pathway networks (GO 
category biological process). The functional pathway networks presented here were 
generated from the GO category biological process. In addition to GO category biological 
process, the KEGG database and the GO category cellular component were used for 
mapping the HuR target mRNAs; the latter results are provided in supplemental tables 4-
6. The package ClusterProfiler was used to perform GO term enrichment and network 
visualization. The enriched terms were defined as those that passed the following filters: 
P value < 0.01, q value < 0.05 and minGSSize > 10. Enrichment was tested using a 
hypergeometric test. To address the issue of false discovery rate, q values were 
calculated. 
AA, amino acid; bio pro, biosynthetic process; cat pro, catabolic process; carb, 
carbohydrate; Chol, cholesterol; comp, compound; ER, endoplasmic reticulum; FA, fatty 
acid; LDL, low density lipoprotein; lip, lipid; met pro, metabolic process; pos reg, positive 
regulation; pro, process; pw, pathway; ROS, reactive oxygen species; reg, regulation; 
res, response; sig pw, signaling pathway; trans, transport; TCA, tricarboxylic acid; UP, 
unfolded protein; UPR, unfolded protein response; ubi, ubiquitination.
Figure 7. Osteopontin partially mediates fibrosis development in HuRHepKO mice
(A) qRT-PCR analysis for Spp1 (encoding for osteopontin, OPN) in livers of HuRWT and 
HuRHepKO mice, which were fed a ND for 6 weeks. Spp1 gene expression was normalized 
to expression of 18s. Data are presented relative to the HuRWT mice, set as 1. n = 7 mice 
in HuRWT group and n = 6 mice in HuRHepKO group. **P < 0.01. Data are presented as 
mean ± s.e.m. Mann-Whitney U test.
(B) qRT-PCR analysis for Spp1 in livers of HuRWT and HuRHepKO mice, which were fed a 
60%-HFD-CD for 6 weeks. Spp1 gene expression was normalized to expression of 18s. 
Data are presented relative to the HuRWT mice, set as 1. n = 8 mice in HuRWT group and 
n = 5 mice in HuRHepKO group. **P < 0.01. Data are presented as mean ± s.e.m. Mann-
Whitney U test.
(C) Osteopontin (OPN) protein was measured in conditioned medium derived from 
HuRWT or HuRHepKO primary hepatocytes. N = 7. *P < 0.05. Data are presented as mean ± 
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(D) Quantification and (E) representative images of picrosirius red staining in livers of 
HuRHepKO mice, which were fed a 60%-HFD-CD for 2 weeks and treated with the 
osteopontin neutralizing antibody (OPN Ab) or control IgG antibody (IgG). n = 6 mice / 
group. Data are presented as mean ± s.e.m. Mann-Whitney U test. Scale bar, 100 μm. 
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